Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul;67(7):1370-1378.
doi: 10.1111/jgs.15839. Epub 2019 Mar 20.

Influence of Multimorbidity on Burden and Appropriateness of Implantable Cardioverter-Defibrillator Therapies

Affiliations

Influence of Multimorbidity on Burden and Appropriateness of Implantable Cardioverter-Defibrillator Therapies

Alexandra M Hajduk et al. J Am Geriatr Soc. 2019 Jul.

Erratum in

  • Corrigendum.
    [No authors listed] [No authors listed] J Am Geriatr Soc. 2019 Nov;67(11):2430. doi: 10.1111/jgs.16175. Epub 2019 Sep 17. J Am Geriatr Soc. 2019. PMID: 31736070 No abstract available.

Abstract

Objective: To determine whether burden of multiple chronic conditions (MCCs) influences the risk of receiving inappropriate vs appropriate device therapies.

Design: Retrospective cohort study.

Setting: Seven US healthcare delivery systems.

Participants: Adults with left ventricular systolic dysfunction receiving an implantable cardioverter-defibrillator (ICD) for primary prevention.

Measurements: Data on 24 comorbid conditions were captured from electronic health records and categorized into quartiles of comorbidity burden (0-3, 4-5, 6-7 and 8-16). Incidence of ICD therapies (shock and antitachycardia pacing [ATP] therapies), including appropriateness, was collected for 3 years after implantation. Outcomes included time to first ICD therapy, total ICD therapy burden, and risk of inappropriate vs appropriate ICD therapy.

Results: Among 2235 patients (mean age = 69 ± 11 years, 75% men), the median number of comorbidities was 6 (interquartile range = 4-8), with 98% having at least two comorbidities. During a mean 2.2 years of follow-up, 18.3% of patients experienced at least one appropriate therapy and 9.9% experienced at least one inappropriate therapy. Higher comorbidity burden was associated with an increased risk of first inappropriate therapy (adjusted hazard ratio [HR] = 1.94 [95% confidence interval {CI} = 1.14-3.31] for 4-5 comorbidities; HR = 2.25 [95% CI = 1.25-4.05] for 6-7 comorbidities; and HR = 2.91 [95% CI = 1.54-5.50] for 8-16 comorbidities). Participants with 8-16 comorbidities had a higher total burden of ICD therapy (adjusted relative risk [RR] = 2.12 [95% CI = 1.43-3.16]), a higher burden of inappropriate therapy (RR = 3.39 [95% CI = 1.67-6.86]), and a higher risk of receiving inappropriate vs appropriate therapy (RR = 1.74 [95% CI = 1.07-2.82]). Comorbidity burden was not significantly associated with receipt of appropriate ICD therapies. Patterns were similar when separately examining shock or ATP therapies.

Conclusions: In primary prevention ICD recipients, MCC burden was independently associated with an increased risk of inappropriate but not appropriate device therapies. Comorbidity burden should be considered when engaging patients in shared decision making about ICD implantation.

Keywords: chronic disease; comorbidity; implantable cardioverter-defibrillator; multimorbidity; patient-centered outcomes.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Frequencies of shock/ATP, stratified by quartiles of comorbidity count in adults with a primary prevention ICD.
Figure 2.
Figure 2.. Association of baseline counts of comorbidities and time to first shock/ATP among 2235 participants who received a primary prevention ICD for cox proportional hazard regression models.
Panel A represents results for time to first delivered device therapy of any type; panel B represents time to first inappropriate device therapy, and panel C represents time to first appropriate device therapy.
Figure 3.
Figure 3.. Association of baseline counts of comorbidities and burden of total delivered shocks/ATPs among 2235 participants who received a primary prevention ICD.
Panel A represents results for burden of device therapy of any type; panel B represents burden of inappropriate device therapy, and panel C represents burden of appropriate device therapy.
Figure 4.
Figure 4.
Association of baseline counts of comorbidities with risk of receiving an inappropriate shock/ATP vs. appropriate shock/ATP among 562 adults who received at least one inappropriate or appropriate shock from primary prevention ICD.

Similar articles

Cited by

References

    1. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346: 877–883. - PubMed
    1. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352: 225–237. - PubMed
    1. Tung P, Albert CM. Causes and prevention of sudden cardiac death in the elderly. Nature reviews Cardiology. 2013;10: 135–142. - PubMed
    1. Peck KY, Lim YZ, Hopper I, Krum H. Medical therapy versus implantable cardioverter -defibrillator in preventing sudden cardiac death in patients with left ventricular systolic dysfunction and heart failure: a meta-analysis of > 35,000 patients. International journal of cardiology. 2014;173: 197–203. - PubMed
    1. Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2013;127: e283–352. - PubMed

Publication types